Surgical treatment of tricuspid regurgitation after mitral valve surgery: a retrospective study in China by Li, Zong-Xiao et al.
RESEARCH ARTICLE Open Access
Surgical treatment of tricuspid regurgitation after
mitral valve surgery: a retrospective study in
China
Zong-Xiao Li
1†, Zhi-Peng Guo
1, Xiao-Cheng Liu
1†, Xiang-Rong Kong
1,2†, Wen-Bin Jing
1†, Tie-Nan Chen
1, Wan-Li Lu
1
and Guo-Wei He
1,2,3*†
Abstract
Background: Functional tricuspid regurgitation (TR) occurs in patients with rheumatic mitral valve disease even
after mitral valve surgery. The aim of this study was to analyze surgical results of TR after previous successful mitral
valve surgery.
Methods: From September 1996 to September 2008, 45 patients with TR after previous mitral valve replacement
underwent second operation for TR. In those, 43 patients (95.6%) had right heart failure symptoms (edema of
lower extremities, ascites, hepatic congestion, etc.) and 40 patients (88.9%) had atrial fibrillation. Twenty-six patients
(57.8%) were in New York Heart Association (NYHA) functional class III, and 19 (42.2%) in class IV. Previous
operations included: 41 for mechanical mitral valve replacement (91.1%), 4 for bioprosthetic mitral valve
replacement (8.9%), and 7 for tricuspid annuloplasty (15.6%).
Results: The tricuspid valves were repaired with Kay’s (7 cases, 15.6%) or De Vega technique (4 cases, 8.9%).
Tricuspid valve replacement was performed in 34 cases (75.6%). One patient (2.2%) died. Postoperative low cardiac
output (LCO) occurred in 5 patients and treated successfully. Postoperative echocardiography showed obvious
reduction of right atrium and ventricle. The anterioposterior diameter of the right ventricle decreased to 25.5 ± 7.1
mm from 33.7 ± 6.2 mm preoperatively (P < 0. 05).
Conclusion: TR after mitral valve replacement in rheumatic heart disease is a serious clinical problem. If it occurs
or progresses late after mitral valve surgery, tricuspid valve annuloplasty or replacement may be performed with
satisfactory results. Due to the serious consequence of untreated TR, aggressive treatment of existing TR during
mitral valve surgery is recommended.
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Background
Mitral valve replacement (MVR) has been the most
common surgical procedure for rheumatic mitral valve
disease including stenosis and incompetence. Functional
tricuspid regurgitation (TR) is frequently associated with
rheumatic mitral valve disease in the patients under-
going MVR. In addition, in patients who had previous
mitral valve replacement, TR is also a frequently
encountered complication.
Which patient undergoing mitral valve surgery should
also have the tricuspid repair is an important clinical
question [1]. It was proposed to treat TR independently
from the grade of regurgitation when the annular
dimension is over 21 mm/m
2 or more than or equal to
3.5 cm at echocardiography measurement or when the
intra-operative tricuspid annulus (TA) diameter is > 70
mm [1], although others suggested that echocardio-
graphic tricuspid annular dimensions alone, in the
absence of significant (less or equals to 1+) TR
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tricuspid repair [2]. However, for TR after MVR, the
opinion for treatment is still in controversy. Most
recently, Rogers and associates [3] suggested that if
untreated at the time of surgical mitral valve repair, sig-
nificant residual TR negatively impacts perioperative
outcomes, functional class, and survival and that TR
does not reliably resolve after successful mitral valve
surgery. Further, if present at the time of mitral valve
surgery, TR can usually be effectively addressed with
ring annuloplasty. Because reoperations for recurrent
TR carry high mortality rates, few patients are offered
reoperation for redo tricuspid repair or replacement.
We therefore, in the present study, report our experi-
ence in surgical treatment of TR post-mitral surgery.
Methods
Clinical data
From September 1996 to September 2008, a consecutive
series of 45 patients who had second operation for TR
after mitral valve replacement in the TEDA Interna-
tional Cardiovascular Hospital and previously incorpo-
rated hospitals were retrospectively enrolled in this
study. The patients who had concomitant surgery apart
from mitral valve replacement at the first operation or
during the second operation for the TR were excluded
from the present study. There were 12 male (26.7%) and
33 female patients with median age of 49 year-old, ran-
ging 27-69 years. All patients were diagnosed rheumatic
heart disease. Forty-three patients (95.6%) had right
heart failure symptoms (edema of lower extremity,
ascites, hepatic congestion, etc.). Forty patients (88.9%)
had persistent atrial fibrillation. Only 5 patients were in
sinus rhythm (11.1%). Patients who had severe TR by
echocardiography (24 patients, 53.3%) had clinical TR.
Twenty-six patients (57.8%) were in New York Heart
Association (NYHA) functional class III, and 19 (42.9%)
in class IV. The chest X ray showed that all patients had
enlarged heart with the cardiothoracic ratio more than
55%. The average time from the pervious operation was
6.8 ± 3.4 years (x ± SD). The previous operations
included: mechanical mitral valve replacement (41,
91.1%), bioprosthetic mitral valve replacement (4, 8.9%),
and tricuspid annuloplasty (7, 15.6%).
All patients were investigated preoperatively by means
of Doppler echocardiography. In our grading system,
mild TR = grade 1; moderate TR = grade 2 and 3;
severe TR = grade 4. Echocardiography showed moder-
ate TR in 21 cases (46.7%) and severe TR in 24 patients
(53.3%).
The systolic pressure of pulmonary artery was 57.3 ±
19.6 mmHg (x ± SE).
Common laboratory findings in those patients were:
elevation of transaminase (in 40 patients, 88.9%),
hypoalbuminemia and anemia (in 4 patients, 8.9%).
Blood urea nitrogen and creatinine increased in 1 case
(2.2%).
All patients received digoxin and diuretic therapy to
improve the cardiac function preoperatively. The heart
rates were controlled by medications in those patients
with rapid atrial fibrillation. The patients with anemia
(Hb < 8 g/L) or hypoproteinemia were transfused with
red blood cells or albumin. The Characteristics of the
patients are listed in Table 1.
Surgical procedures
All patients underwent the operation with general
anesthesia and intubation. The sternotomy was per-
formed with swing saw with the adhesion carefully dis-
sociated and the wires removed. Cardiopulmonary
Table 1 Patient Characteristics
Sex
Male 12
Female 33
Rheumatic Heart Disease
45
NYHA Class
I-II 0
III 26
IV 19
Atrial fibrillation
40
Mitral Valve Replacement (first op.)
Mechanical 41
Bioprosthetic 4
Tricuspid Annuloplasty (first op.)
7
Tricuspid Regurgitation
Moderate 21
Severe 24
Preoperative Medicine
Digoxin 45
Furosemide 11
Hydrochlorothiazide 35
Spironolactone 44
Tricuspid Operation
Annuloplasty
De Vega 4
Kay 7
Replacement
Mechanical 22
Bioprosthetic 12
Af : atrial fibrillation
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were either tricuspid annuloplasty or valve replacement.
The decision to perform valve replacement was mainly
due to the preference of the patient and the surgeon
(XRK). Unlike in the Western countries, in China most
patients prefer “one-surgery-only” procedures to avoid
future operations. In this experience, most tricuspid
valve replacements were performed due to the request
of the patient by one surgeon (XRK) while the annulo-
plasty was performed by others.
Tricuspid annuloplasty was performed with annulo-
plasty, either semicircular (classical or modified De Vega
repair, 4 cases) or simple lateral annuloplasty (Kay
repair, 7 cases). Due to cost of the tricuspid annulo-
plasty ring and the extensive experience on tricuspid
repair in the primary tricuspid valve surgery by the sur-
geons (XCL, WBJ, and GWH) in this group, no rings
were used in this experience.
Thirty-four patients had valve replacement with either
mechanical (22) or bioprosthesis (12). The details of the
prosthesis used are listed in Table 2.
Statistical analysis
Data were described as mean ± standard deviation
(x ± SD), or median [quartiles] (median [25%, 75%]).
Paired t-test was used to compare the pre- and post-
operative cardiac function. The data were analyzed with
ANOVA by using SPSS 13.0. P < 0.05 was considered
statistically significant.
Results and discussion
As described above, the tricuspid annuloplasty was per-
formed in 11 patients with Kay’s (7 cases, 15.6%) or De
Vega technique (4 cases, 8.9%).
In patients received tricuspid valve replacement (34
cases, 75.6%), 2 cases initially had annuloplasty that was
demonstrated unsatisfactory by intraoperative transeso-
phageal echocardiography after the repair and tricuspid
valve replacement was then immediately performed.
One patient who had tricuspid valve replacement died
(2.2%) due to severe left ventricular dysfunction that
caused refractory low cardiac output postoperatively.
There was no mortality in the tricuspid repair group. In
addition, postoperative low cardiac output syndrome
occurred in other 5 patients that were treated success-
fully. Regarding the occurrence of low cardiac output,
there were no differences between the tricuspid valve
replacement group (4/34, 11.8%) and tricuspid repair
group (1/11, 9.1%, p > 0.05). There were no differences
between the two groups with regard to the hospital stay,
inotropic support, and pre- and post-operative NYHA
class.
Before discharge, postoperative echocardiography
showed significant reduction of the right atrium and
ventricle in all patients. The anterioposterior diastolic
diameter of the right ventricle decreased to 23-41 mm
(25.5 ± 7.1 mm), comparing with the preoperative data
of 31 ~ 48 mm (33.7 ± 6.2 mm, P < 0. 05).
Follow-up
Owing to the fact that some patients were from remote
rural areas and that due to the rapidly growing economy
in China the habitation of the rural population is fre-
quently and uncontrollably movable, follow-up on this
group of patients was extremely difficult. All patients
were followed at 6 months with echocardiography at
either our outpatient clinic or the local hospital. How-
ever, there were only 25 patients successfully followed
beyond 1.5 years. The average follow-up period was 6.8
± 3.4 years, ranging from 1.5-12 years.
At the follow-up, all patients had improvement in car-
diac function (Figure 1). The average NYHA functional
class was significantly improved from preoperative 3.32
Table 2 The details of the prostheses used for tricuspid
valve replacement during the re-operation
Mechanical prosthesis
(ATS)
Bioprosthesis
(BalMedic)
Size (mm) 23 25 27 29 31 23 25 27 29 31
Patient number 0 0 13 9 0 0 0 7 5 0
0.5
1.5
2.5
3.5
Pre-op Post-op
N
Y
H
A
 
C
l
a
s
s
n=1
n=6
n=1
n=3
n=12
n=2
Č
ċ
Ċ
ĉ
Figure 1 Comparison between the preoperative cardiac
function and the cardiac function at the follow-up. NYHA Class:
New York Heart Association functional class.
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ure 1, 8 patients who were in NYHA Class IV preopera-
tively were in class I, II, or III during the follow-up.
Similarly, 14 of 17 patients who were in NYHA class III
preoperatively were in class I or II at the follow-up.
Treatment of TR after mitral valve replacement is a
rather complicated issue. First, the TR could be residual
one that presented at the first operation but not treated
during the operation. Second, the TR could be the
newly-developed one that was due to continuous patho-
logical progress after the mitral surgery.
Although the short-term outcome of mitral valve
replacement without dealing with TR may be satisfac-
tory, unacceptably high rates of residual and/or recur-
rent TR at the mid- and long-term remain a problem
for clinical challenging.
The repair of TR at the first mitral operation is an
interesting topic. In the present study, only 7 patients
(15.6%) received tricuspid annuloplasty in the previous
operation. This is probably due to the reason that in the
early period it was a general belief that mild and moder-
ate TR, either of functional or of organic cause, would
be improved after surgical correction of left-side valvular
lesions [4]. However, it was reported later that the inci-
dence of severe TR post mitral valve operation is about
10%-16% [5,6], despite sometimes no obvious TR was
observed during the previous operation. In fact, Matsu-
naga and associates investigated 70 patients who under-
went mitral valve repair and found that the incidence of
TR increased from 25% at 1 year to 53% between 1 and
3 years, and 74% at 3 years [7]. Similarly, Dreyfus and
colleagues found that in about 50% of the cases of
mitral valve repair the tricuspid annulus was abnormally
dilated, even in the absence of TR. In the late follow-up,
the patients who did not have a tricuspid annuloplasty
had progressive tricuspid dysfunction. Therefore, they
recommended “prophylactic” tricuspid annuloplasty [8].
The causes of functional TR after mitral valve surgery
may include: (1) continuing expansion of right ventricle
and tricuspid annulus; (2) persistent pulmonary artery
hypertension that may cause right ventricular dilatation
and dysfunction [9]; (3) residual stenosis and insuffi-
ciency of mitral valve lead to functional TR; (4) myocar-
dial fibrosis in patient with rheumatic heart disease that
can aggravate the right ventricular dysfunction, which is
followed by TR; (5) severe cardiac arrhythmia that wor-
sens the right ventricular function; (6) right ventricular
dysfunction following intraoperative or postoperative
ventricular ischemia; and (7) the presence of a trans-tri-
cuspid pacemaker lead that is another known factor for
late TR development secondary to adhesions and fibrous
retraction [1].
Based on the above reasons, GoTo and colleagues
believed that tricuspid insufficiency with advanced
mitral valve disease, even of a slight degree, should be
surgically treated and that annuloplasty has more
obvious hemodynamic benefits than valve replacement
[10]. It is now more or less the commonly accepted
concept that aggressive treatment of TR during the first
valve surgery would benefit the cardiac function, parti-
cularly the right heart function, for the long term
[10,11].
In this study, 43 patients (95.6%) had right heart fail-
ure symptoms and the majority of patients were in atrial
fibrillation. Similarly, most patients were in New York
Heart Association NYHA functional class III or IV.
These data indicated the severity of the condition of the
patient with TR post-mitral surgery. Furthermore, even
long-period medical therapy could not release the symp-
toms and improve the quality of life in those patients
and therefore an aggressively surgical treatment was
strongly indicated.
From the present study, we would like to emphasize
that it is necessary to treat the patient with proper med-
ications preoperatively (see Table 1 for details)in order
to improve cardiac function particularly the right ventri-
cle function and the general condition of the patient.
Such preparations are necessary in order to reduce the
incidence of post-operative low output syndrome or
other complications.
The surgical procedure of correction of TR is usually
the surgeon’s preference. Several techniques are avail-
able to correct functional tricuspid regurgitation [12].
The recommended methods include: the tricuspid annu-
loplasty by using simple stitches, such as semicircular
(classical or modified De Vega repair) or simple lateral
annuloplasty (Kay); novel techniques such as edge-to-
edge or clover technique and suture bicuspidization
t e c h n i q u e ;u s eo ff l e x i b l ea n dr i g i dp r o s t h e t i cr i n g so r
3D rings; flexible prosthetic bands; and use of artificial
chordae with polytetrafluoroethylene sutures for anterior
and septal tricuspid leaflet pathology [12,13].
Mangoni et al. [14] reported a high mortality after iso-
lated tricuspid valve replacement. We found that our
study had a different population compared with theirs.
They reported “undergoing isolated tricuspid valve
replacement from 1984 to 1996. The cause of valve dys-
function was rheumatic heart disease in 12 patients,
healed endocarditis in two patients, and sarcoidosis in
one patient.” They dealed with a very rare group of
patients with tricuspid valve diseases who did not have
mitral valve diseases. In contrast, our patients were
those who underwent mitral valve replacement at the
first instance and then had the second operation for
severe tricuspid regurgitation. Similarly, Kim et al. [15]
reported 61 patients with isolated severe tricuspid regur-
gitation undergoing corrective surgery and they had 10%
hospital mortality and 3 patients died during follow-up.
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was different from ours but similar to the patient popu-
lation of Mangoni and associates. Clearly the different
results obtained by us and by Mangoni or Kim and their
colleagues were mainly due to completely different
patient populations.
The landmark studies on the tricuspid valve surgery
[16,17] reviewed two series that had higher mortality,
indicating the seriousness of the patient conditions and
the superiority of the annuloplasty ring over simple
sutures [16]. In the present study, we had low mortality
compared to their series. This is partially because of the
different patient populations. McCarthy and colleagues
described a severe TR in their patients for the first
operation whereas our patients usually had less TR dur-
ing the first operation but the TR was more severely
developed after the mitral surgery. Nevertheless, the
advancement of cardiopulmonary and operative techni-
q u em u s ta l s op l a y e dar o l es i n c eo u rp a t i e n t sw e r e
operated more recently than the patients in the series by
Bernal and colleagues [17] who were operated Between
1976 and 2002.
Most tricuspid valve replacements were performed
due to the request of the patient and the surgeon’sp r e -
ference that also played a role since most of tricuspid
valve replacement was performed by one surgeon (XRK)
while others preferred tricuspid annuloplasty. Further, in
our most recent practice, we (ZXL, XCL, WBJ, and
GWH) prefer annuloplasty in the tricuspid position
even in the second operation. This principle is actually
more acceptable most recently [18]. As reported by
Singh and colleagues, tricuspid valve repair is associated
with better perioperative, midterm, and event-free survi-
val than replacement in patients with organic tricuspid
disease. We agree that repair should be performed
whenever possible in patients with organic tricuspid dis-
ease [18].
Similarly, the choice of the prosthesis was also the
preference of the patient. In China, again, due to the
economic status, many patients request to have mechan-
ical prostheses for the durability and this is why more
than half of the patients received mechanical prostheses
in this experience.
From the present study, we believe that after mitral
valve surgery, for those patients with moderate TR,
moderate pulmonary hypertension, and without severe
dilatation of tricuspid valve annulus, tricuspid annulo-
plasty is indicated. However, if the patient has severe
TR and symptoms of heart failure before operation, or
has had annuloplasty in the previous surgery, valve
replacement may be considered. Postoperative echocar-
diography showed excellent results of these procedures
with significant reduction of the right atrium and ventri-
cle and improvement of cardiac function.
Limitation of Study
This study was composed of the experience from a
group of surgeons who have their own preference for
tricuspid valve replacement or repair, and for the
method of repair. Therefore, the uniform opinion as to
the indication for tricuspid replacement or repair was
not formed although all surgeons in this group agree
that for the significant tricuspid regurgitation at mitral
valve surgery and for the recurrent tricuspid regurgita-
tion developed after the mitral surgery, the active surgi-
cal treatment is necessary. Further, due to the
geographic limitations, the follow-up is limited. To
reach the definite conclusion for the procedure to treat
the tricuspid regurgitation, longer follow-up would be
essential in the future.
Conclusions
In summary, TR after mitral valve replacement in
rheumatic heart disease is a serious clinical problem. If
it occurs or progresses late after mitral valve surgery,
active surgical treatment should be indicated with
either tricuspid valve annuloplasty or replacement that
may lead to satisfactory results. Due to the serious
consequence of untreated TR, aggressive treatment of
existing TR during mitral valve surgery is
recommended.
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